Type 2 Diabetes Trial, Recruiting NCT06764069 Sponsor: Glucotrack Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT06764069
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 21 to 75 years old (inclusive)
  • People who are generally in good health, as determined by the trial doctor
  • People who have a confirmed diagnosis of type 1 or type 2 diabetes, supported by medical records
  • People who manage their diabetes with intensive insulin therapy — either 3 or more injections per day, or an insulin pump
  • People whose HbA1c (a blood sugar average reading) was below 9.0% in the last 3 months
  • People with good enough veins for blood draws, as assessed by trial staff
  • People who are willing to stay in hospital for up to 5 days as part of the study
  • People who are willing to do up to 7 fingerstick blood sugar checks per day using study-provided equipment
  • People who are willing to wear a continuous glucose sensor under the skin for the whole study period
  • People who are willing to carry a study-provided Android phone at all times during the study
  • People who have access to the internet for periodic uploads of study device data
  • People with a BMI between 18 and 35 kg/m²
  • People who are able to understand and follow study procedures and give informed consent, and who are proficient in English or have access to a Portuguese-to-English translator

Who may not be able to join:

  • People who are currently taking Acetaminophen (paracetamol) and are unable to switch to a different pain reliever
  • People who are currently taking blood-thinning (anticoagulant) medication
  • People with a history of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), or a blood clotting disorder that the trial doctor believes could affect safety
  • People currently using certain non-insulin diabetes medications, specifically SGLT2 inhibitors or Insulin Secretagogues
  • Women of childbearing potential who test positive on a pregnancy screening test
  • Women of childbearing potential who are planning to become pregnant, or who are not using a reliable form of contraception as judged by the trial doctor
  • People who have had one or more episodes of severe low blood sugar (hypoglycaemia) or diabetic ketoacidosis (DKA) in the last 6 months that required medical care or help from another person
  • People whose red blood cell level (haematocrit) is below the normal reference range
  • People with known heart or cardiovascular disease that the trial doctor considers clinically significant
  • People currently being treated with systemic (oral or intravenous) corticosteroids, or who have used them within the last 8 weeks
  • People taking thyroid hormones whose dose has not been stable for at least the past 3 months
  • People with a significant history of alcoholism or drug abuse that, in the trial doctor's opinion, could affect safety or study results
  • People with a significant acute or chronic illness that, in the trial doctor's opinion, could interfere with safety or the reliability of study results
  • People who are currently participating in another clinical drug or device study
  • People who are part of the research staff conducting this study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 6198892412

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Glucotrack
Registry
ClinicalTrials.gov
Start date
13 December 2024
Est. completion
4 February 2025

Where this trial is recruiting

🇧🇷 Brazil

Primary endpoints

Primary outcome: study device safety as evidence by absence of serious procedure or device related adverse event(s).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov